SK Pharmteco
SK Pharmteco is a global CDMO and subsidiary of SK Inc., offering integrated small molecule, peptide, and viral vector manufacturing services to pharmaceutical and biotechnology companies across the U.S., Europe, and South Korea.
- Company typePrivate
- Founded2024
- HeadquartersRancho Cordova, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What SK Pharmteco does
SK Pharmteco is a global contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of South Korea's SK Inc., formed in December 2024 through the consolidation and rebrand of SK Biotek, YposKesi, and Center for Breakthrough Medicines. The company operates three business units—small molecules, peptides, and viral vectors—serving pharmaceutical and biotechnology developers from early clinical development through commercial scale. Headquartered in Rancho Cordova, California, SK Pharmteco employs more than 10,000 people across CGMP manufacturing facilities in the United States (California, Texas, Pennsylvania), Europe (Ireland, France), and South Korea, with over 1,000 m³ of small molecule capacity and 5,000+ liters of viral vector bioreactor capacity.
The company's technology platform centers on the proprietary SKyvec™ multimodal viral vector system (AAV, lentiviral, adenoviral), a Universal CGMP HEK293 cell line (Clone 4G9), the Analytical Accelerator™ testing platform that reduces batch release time more than three-fold, seven Simulated Moving Bed chromatography units (including the largest in North America), continuous flow processing under extreme conditions (up to 300 bar, 600°C), HPAPI containment to 10 ng/m³ OEL, and a 6,000+ enzyme biocatalyst library accessed through the Prozomix partnership. The company is pursuing SBTi-validated net-zero emissions by 2040 and holds multiple My Green Lab certifications. Revenue is generated primarily through fee-for-service CDMO contracts, project-based and scale-dependent, spanning clinical trial materials through commercial API and viral vector production, with multi-year commercial manufacturing relationships providing recurring revenue visibility—a $1.4 billion GLP-1 manufacturing deal secured in December 2024 is the largest disclosed commercial anchor.
SK Pharmteco firmographics
Firmographics- Name
- SK Pharmteco
- Legal name
- SK pharmteco Inc.
- Website
- https://skpharmteco.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- SK Pharmteco is a global CDMO and subsidiary of SK Inc., offering integrated small molecule, peptide, and viral vector manufacturing services to pharmaceutical and biotechnology companies across the U.S., Europe, and South Korea.
- Ownership category
- akta.pro rank
SK Pharmteco industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where SK Pharmteco is headquartered
LocationHeadquarters
- HQ city
- Rancho Cordova
- HQ country
- United States
- HQ region
- North America
Offices8 records
Markets served
SK Pharmteco business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Manufacturing Services (Small Molecules, Peptides, Viral Vectors): SK pharmteco generates revenue primarily through fee-for-service CDMO contracts covering process development, analytical development, CGMP manufacturing, and quality control services. Revenue is project-based and scale-dependent, spanning clinical trial materials manufacturing through commercial-scale API and viral vector production. The company operates across three business units (small molecules, peptides, viral vectors) and serves pharmaceutical and biotech clients globally, with multi-year commercial manufacturing relationships providing recurring revenue visibility.
- Viral Vector Manufacturing: Viral vector CDMO services including AAV, lentiviral, and adenoviral vector manufacturing from early development through commercial supply. The company has invested $100 million to expand viral vector capabilities in Pennsylvania and France, positioning for growth in the high-value gene therapy CDMO market. Manufacturing scales up to 1,000 liters (U.S.) and 2,000 liters (France) under GMP conditions.
- SKyvec™ Platform Licensing/Access: Access to proprietary multimodal viral vector platforms (AAV, Lentiviral, Adenoviral) combined with manufacturing services, with process enhancements delivering 5x–6x productivity gains. Platform is positioned as a differentiated offering that addresses industry scalability and cost challenges in gene therapy manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for CDMO services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
SK Pharmteco product offering
Product offeringCore offering
SK Pharmteco is a global contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services across three business units: small molecules (APIs, intermediates, HPAPIs, ADC payloads), peptides (synthesis and purification), and viral vectors (AAV, lentiviral, adenoviral). The company operates CGMP facilities across the U.S., Europe, and South Korea, delivering end-to-end services from process development and analytical testing through clinical and commercial-scale manufacturing for pharmaceutical and biotechnology clients.
Product overview
SK pharmteco is a global contract development and manufacturing organization (CDMO) organized around three core business units: Small Molecules, Peptides, and Viral Vectors. The company operates as a unified platform providing end-to-end pharmaceutical manufacturing services from early development through commercial scale. The Small Molecules unit encompasses API drug development, custom manufacturing, and specialty capabilities including chromatography, energetic chemistry, HPAPIs, continuous flow processing, particle engineering, catalyst design, and biocatalysis. The Peptides unit provides integrated peptide synthesis and purification services. The Viral Vectors unit is anchored by the proprietary SKyvec™ multimodal platform supporting AAV, lentiviral, and adenoviral vector manufacturing, complemented by the AAVelocity platform. Supporting services include analytical testing, regulatory support, cell and viral banking, fill-finish operations, and rare disease program support. The company operates CGMP facilities across the U.S. (California, Texas, Pennsylvania), Europe (Ireland, France), and South Korea.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule CDMO Services Scalable small molecule development and manufacturing of active pharmaceutical ingredients (APIs), regulatory starting materials, advanced intermediates, and high-potency APIs spanning from grams to multi-tons under CGMP compliance, including specialty capabilities such as chromatography, energetic chemistry, continuous flow processing, particle engineering, catalyst design, and biocatalysis.
- Peptide CDMO Services Integrated peptide development and manufacturing combining advanced synthesis (SPPS, LPPS, hybrid approaches), chromatographic purification, and in-house analytics for clinical to commercial scale peptide APIs, supporting peptide therapeutics including GLP-1 receptor agonists for metabolic disease applications.
- Viral Vector CDMO Services Viral vector manufacturing platforms and customized solutions for AAV, lentiviral, and adenoviral vectors supporting programs from early development through clinical and commercial manufacturing, including process development, CGMP drug substance manufacturing, aseptic fill-finish, cell and viral banking, and analytical services.
- SKyvec™ Viral Vector Platform Harmonized multimodal viral vector platform integrating AAV, lentiviral, and adenoviral vector process development, manufacturing, and scale-up. Combines the Universal CGMP HEK293 cell line (clone 4G9), off-the-shelf plasmid technologies, and proprietary processing enhancements to support gene therapy programs from early research through commercial manufacturing across North America and Europe.
- Analytical Services End-to-end analytical services including method development and validation, raw material testing, characterization, release testing, and stability studies for small molecule APIs, peptides, and viral vectors. Includes the proprietary Analytical Accelerator™ Testing Platform that speeds CGMP batch release more than three-fold and conserves sample volumes by up to 50 percent.
- Regulatory Support Services
Quantifiable outcome
- 5x to 6x productivity gains in viral vector manufacturing through SKyvec™ platform
- +9 more outcomes
Companies that use SK Pharmteco
Customer profileNamed customers11 records
Segments6 records
Ideal customer profiles5 records
SK Pharmteco technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
SK Pharmteco partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered strategic and core.
- Orphan ClinDevNet (Orphan Therapeutics Accelerator Network)strategicSK pharmteco joined Orphan Therapeutics Accelerator's expanded development network, Orphan ClinDevNet, alongside OPIS, Uniphar, and TMC Pharma. The network provides a decentralized, outsourced infrastructure for development and commercialization of ultra-rare disease therapies. SK pharmteco contributes U.S.-based viral vector manufacturing capabilities to the network.
- Orphan Therapeutics Accelerator (OTXL)coreStrategic collaboration making SK pharmteco OTXL's preferred technical partner for manufacturing services for rare disease therapies. SK pharmteco provides priority access and preferential rates for up to two therapeutic programs per year, encompassing process development, analytical development, and GMP manufacturing. The partnership aligns with SK pharmteco's Rare Disease Advancement Initiative and aims to address common manufacturing challenges preventing rare disease programs from progressing to clinical and commercial stages. OTXL is a non-profit biotech focused on advancing stalled rare disease treatments.
- National Institutes of Health (NIH)coreSK pharmteco serves as subcontractor to NIH (with Axle Informatics as prime contractor) for gene therapy programs for rare diseases, focusing on viral vector programs including lentiviral vectors for treating rare hereditary blood and metabolic disorders. SK pharmteco manufactured drug substance and conducted batch release testing for ex vivo transduction of patients' CD34+ hematopoietic stem cells. The collaboration combines SK pharmteco's advanced manufacturing capabilities with NIH principal investigators to accelerate academic research into clinical practice.
- Axle InformaticscoreAxle Informatics serves as the primary contractor to NIH for gene therapy programs, with SK pharmteco as subcontractor providing viral vector manufacturing and analytical support. The collaboration leverages Axle's bioinformatics and program coordination expertise with SK pharmteco's manufacturing capabilities for rare disease gene therapy development.
- ProzomixcoreStrategic partnership integrating Prozomix's biocatalyst libraries (over 6,000 diverse native biocatalysts) into SK pharmteco's small-molecule development and manufacturing services across R&D centers in the U.S., Europe, and Asia. The collaboration enables rapid identification of high-performing enzymes for complex Active Pharmaceutical Ingredient synthesis, accelerating adoption of sustainable, enzyme-based manufacturing processes. The deal expands SK pharmteco's technology offerings while providing Prozomix access to a broader spectrum of high-value pharmaceutical projects through SK pharmteco's worldwide manufacturing network.
- Lotte BiologicsstrategicStrategic partnership between SK pharmteco and Lotte Biologics to strengthen global ADC CDMO capabilities. The collaboration aims to enhance both companies' positions in the antibody-drug conjugate contract development and manufacturing organization market, strengthening their global presence in this biotech sector through complementary capabilities.
- AaviGenstrategicStrategic partnership to manufacture AaviGen's lead gene therapy product for heart failure. SK pharmteco provides viral vector manufacturing and development services for AaviGen's cardiac gene therapy program, supporting the company's advancement toward clinical stages.
- CryoportstrategicPartnership for cell and gene therapy logistics and BioServices. Cryoport provides specialized logistics solutions for temperature-sensitive biological materials, complementing SK pharmteco's manufacturing capabilities for cell and gene therapy products requiring reliable cold-chain distribution.
- RznomicsstrategicSK pharmteco and Rznomics signed a Memorandum of Understanding (MoU) to explore collaboration for RNA-based gene therapy development and manufacturing. The partnership aims to combine SK pharmteco's CDMO capabilities with Rznomics' RNA-based gene therapy platform to support development and manufacturing of innovative RNA-based therapeutics.
Scale indicators22 records
Recent moves9 records
Expansion highlights8 records
SK Pharmteco competitors and assessment
Company assessmentDirect peers
- Lonza Group: World's largest CDMO offering integrated small molecule, biologics, and cell & gene therapy manufacturing services globally. Directly comparable as a multi-modality CDMO serving pharma and biotech with similar end-to-end capabilities.
- AGC Biologics: Global CDMO specializing in biologics and viral vector/ cell and gene therapy manufacturing. Closely comparable as a viral vector CDMO with similar gene therapy customer base and manufacturing capabilities.
- Lotte Biologics: Korean CDMO with biologics manufacturing and growing ADC capabilities. Comparable as a Korean-headquartered CDMO peer and strategic ADC partnership partner to SK pharmteco.
- Catalent: Major global CDMO (now owned by Novo Holdings) providing small molecule and biologic drug substance and drug product services. Closely comparable in CDMO scope across modalities and customer base.
- WuXi AppTec / WuXi Biologics: Global CDMO offering small molecule API manufacturing, biologics, viral vectors, and integrated CMC services. Direct peer across multiple CDMO modalities including viral vector manufacturing.
- Recipharm: European CDMO providing small molecule API and finished dosage form manufacturing. Comparable as a multi-site small molecule CDMO serving similar pharmaceutical customers globally.
- Samsung Biologics: Korean biologics CDMO and direct domestic peer within SK pharmteco's Korean ecosystem. Comparable as a large-scale contract manufacturer with biologics and increasingly small molecule capabilities for global pharma.
- Boehringer Ingelheim BioXcellence: Biopharmaceutical contract manufacturing arm of Boehringer Ingelheim offering biologics and viral vector CDMO services. Comparable as a multi-modality CDMO serving similar pharma/biotech customers.
Broad incumbents
- Thermo Fisher Scientific (Patheon): Operates a major CDMO segment (Patheon) plus broader life sciences tools and services. Comparable in small molecule and biologic CDMO services as part of a much larger diversified life sciences platform.
Others
- Center for Breakthrough Medicines (now part of SK pharmteco): Acquired by SK pharmteco in 2023, expanding multi-modality and radiopharmaceutical capabilities. Referenced as a historical peer now integrated into the subject company for cell and gene therapy CDMO services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
SK Pharmteco social profiles
Digital presenceSK Pharmteco compliance and trust
Trust signalCompliance4 records
SK Pharmteco financial estimates
Financial estimateRevenue estimate
Valuation estimate
SK Pharmteco leadership team
Management profileNumber of profiles
Profiles4 records
SK Pharmteco funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SK Pharmteco M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SK Pharmteco
What does SK Pharmteco do?
SK Pharmteco is a global contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services across three business units: small molecules (APIs, intermediates, HPAPIs, ADC payloads), peptides (synthesis and purification), and viral vectors (AAV, lentiviral, adenoviral). The company operates CGMP facilities across the U.S., Europe, and South Korea, delivering end-to-end services from process development and analytical testing through clinical and commercial-scale manufacturing for pharmaceutical and biotechnology clients.
Is SK Pharmteco a public or private company?
SK Pharmteco is a private company. It is classified as corporate owned and is currently operating.
When was SK Pharmteco founded?
SK Pharmteco was founded in 2024. It employs 5,001 to 10,000 people.
Where is SK Pharmteco based?
SK Pharmteco is headquartered in Rancho Cordova, United States, in the North America region.
How does SK Pharmteco make money?
Three revenue lines are on record. CDMO Manufacturing Services (Small Molecules, Peptides, Viral Vectors) is the primary driver. The others are viral Vector Manufacturing and SKyvec™ Platform Licensing/Access.
Who are SK Pharmteco's main competitors?
Direct peers on record are Lonza Group, AGC Biologics, Lotte Biologics, Catalent, WuXi AppTec / WuXi Biologics, Recipharm, Samsung Biologics and Boehringer Ingelheim BioXcellence. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent. Center for Breakthrough Medicines (now part of SK pharmteco) is listed as an others.
Does SK Pharmteco have an API?
No public API is recorded for SK Pharmteco.
What industry is SK Pharmteco in?
SK Pharmteco's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.